Home

Pharmacology

Congress highlights

Expert guidance on management of schizophrenia for a better quality of life and independence

Individualized patient management is key to achieving better lifetime quality of life and...

Congress highlights

Early effects of antidepressants – a clue to mechanism of action

The delay in onset of effect of antidepressant treatment can be frustrating both for the patient...

Depression, Bipolar

Congress highlights

In search of biomarkers for mood disorders

Novel biomarkers for mood disorders will enable early diagnosis and inform the development of new...

Congress highlights

A public invitation to view and comment on pre-final APA schizophrenia guideline statements

Many guidelines exist worldwide on how best to manage psychiatric illnesses, but we never see two...

Depression, Schizophrenia

Congress highlights

Lifestyle, the gut, and mental health

Interventions to lower the risk for cardiovascular disease and metabolic syndrome, correction of...

Positive steps to address negative symptoms in schizophrenia

A goal of precision psychiatry is to locate a patient along the continuum of the disease course,...

The effects of antipsychotic dose reduction/discontinuation on long-term outcome in FEP patients

Patients with FEP often ask whether they can discontinue their medication after a period of...

Does glutamate hold the key to unlocking major depressive disorder?

Despite over 50 years of drug development in major depressive disorder (MDD), patients and their...

Congress highlights

Dopamine D2 partial agonists – efficacy, tolerability and improved functioning?

‘Functioning’ is a broad term, and encompasses the individual’s ability to...

Treatment-resistant schizophrenia – results of a survey on its clinical impact and therapeutic strategies

The results of an online survey completed by 204 US psychiatrists on the clinical impact of...

Brain circuits in depression and response to pharmacotherapy

The symptoms of major depressive disorder (MDD) vary from patient to patient. The primary treatment...

Steps towards more effective and better tolerated treatment options for schizophrenia

New more effective and better tolerated treatments for schizophrenia are needed to improve patient...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind South East Asia Continue to Progress in Mind South Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Finland Continue to Progress in Mind Japan Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Ireland Continue to Progress in Mind Sweden Continue to Progress in Mind Finland

You are leaving Progress in Mind

Continue to

Cancel

You are leaving

Progress in Mind Portugal
HCP Access verification required

To gain access, please provide details to verify you are a healthcare professional.

If you are not located in Portugal click here.

Continue to verification page Login with email

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

Accept

Decline